Milk-derived peptides, val-pro-pro and ile-pro-pro, attenuate atherosclerosis development in apolipoprotein e-deficient mice: A preliminary study

Journal of Medicinal Food

Volumn 16, Issue 5, 2013, Pages 396-403

  Nakamura, Teppei ^a   Hirota, Tatsuhiko ^a   Mizushima, Katsura ^b   Ohki, Kohji ^a   Naito, Yuji ^b   Yamamoto, Naoyuki ^a   Yoshikawa, Toshikazu ^b  

^a CALPIS Co Ltd   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

apoE; atherosclerosis; DNA microarray; Ile Pro Pro; Val Pro Pro

Indexed keywords

8 ISOPROSTANE; APOLIPOPROTEIN E; CAPTOPRIL; CASEIN HYDROLYSATE; ENALAPRIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ARCH; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; INTIMA; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPROTEINS, LDL; MALE; MICE; MICE, KNOCKOUT; MILK; OLIGOPEPTIDES; PROTEIN HYDROLYSATES;

EID: 84877869409     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2012.2541     Document Type: Article

References (31)

1. Giles TD: Atherogenesis and coronary artery disease. In: Hypertension Primer: The Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management, 4th ed. (Izzo JL, Sica DA, Black HR, eds.), Lippincott Williams & Wilkins, Philadelphia, 2008, pp. 209-213.
2. Hayek T, Attias J, Smith J, Breslow JL, Keidar S: Antiathero-sclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 1998;31:540-544.
3. Hayek T, Attias J, Coleman R, et al.: The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999;44:579-587.
4. de Nigris F, D'Armiento FP, Somma P, et al.: Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001;81:107-115.
5. Zanchetti A, Bond MG, Hennig M, et al.: European Lacidipine Study on atherosclerosis investigators: calcium antagonist laci-dipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-2427.
6. Sonoda M, Aoyagi T, Takenaka K, Uno K, Nagai R: A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Heart J 2008;49:95-103.
7. Wing LM, Reid CM, Ryan P, et al.: Second Australian National Blood Pressure Study Group: a comparison of outcomes with angiotensin-converting- enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592.
8. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: LIFE Study Group: cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
9. Dahlöf B, Sever PS, Poulter NR, et al.: ASCOT Investigators: prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
10. Fontana L, Meyer TE, Klein S, Holloszy JO: Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA 2004; 101: 6659-6663.
11. Mellen PB, Liese AD, Tooze JA, Vitolins MZ, Wagenknecht LE, Herrington DM: Whole-grain intake and carotid artery atherosclerosis in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. Am J Clin Nutr 2007;85:1495-1502.
12. Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T: Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 1995; 78:777-783.
13. Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T: A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 1996;64:767-771.
14. Sano J, Ohki K, Higuchi T, et al.: Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension. J Med Food 2005;8:423-430.
15. Nakamura T, Mizutani J, Ohki K, et al.: Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: a randomized, double-blind, placebo-controlled trial. Atherosclerosis 2011;219:298-303.
16. Yoshizawa M, Maeda S, Miyaki A, et al.: Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. Am J Physiol Heart Circ Physiol 2009;297:H1899-H1903.
17. Hirota T, Ohki K, Kawagishi R, et al.: Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res 2007;30:489-496.
18. Zadelaar S, Kleemann R, Verschuren L, et al.: Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007;27:1706-1721.
19. Corella D, Ordovas JM: Nutrigenomics in cardiovascular medicine. Circ Cardiovasc Genet 2009;2:637-651.
20. Baba H, Masuyama A, Takano T: Short communication: effects of Lactobacillus helveticus-fermented milk on the differentiation of cultured normal human epidermal keratinocytes. J Dairy Sci 2006;89:2072-2075.
21. Hirota T, Nonaka A, Matsushita A, et al.: Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings. Heart Vessels 2011;26:549-556.
22. Aihara K, Ishii H, Yoshida M: Casein-derived tripeptide, Val-Pro-Pro (VPP), modulates monocyte adhesion to vascular endo-thelium. J Atheroscler Thromb 2009;16:594-603.
23. Yamauchi T, Nio Y, Maki T, Kobayashi M, et al.: Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13: 332-339.
24. Chen X, Zhang H, McAfee S, Zhang C: The reciprocal relationship between adiponectin and LOX-1 in the regulation of endothelial dysfunction in ApoE knockout mice. Am J Physiol Heart Circ Physiol 2010;299:H605-H612.
25. Xu X, Gao X, Potter BJ, Cao JM, Zhang C: Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler Thromb Vasc Biol 2007;27: 871-877.
26. Chen M, Kakutani M, Minami M, et al.: Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2000;20:1107-1115.
27. Mehta JL, Sanada N, Hu CP, et al.: Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007;100:1634-1642.
28. Morawietz H, Rueckschloss U, Niemann B: Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999;100:899-902.
29. da Cunha V, Tham DM, Martin-McNulty B: Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005;178:9-17.
30. Gross DM, Sweet CS, Ulm EH, et al.: Effect of N-[(S)-1-carboxy-3- phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther 1981;216:552-557.
31. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL: Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endo-thelial nitric oxide synthase double knockout mice. Circulation 2001;104:2391-2394.